Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk-Reference-Cited by-同舟云学术

Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk

Published:2015-03-27 Issue:12 Volume:128 Page:877-882
ISSN:0143-5221
Container-title:Clinical Science
language:en
Short-container-title:

Author:

Guardiola Montse¹,Plana Núria¹,Ibarretxe Daiana¹,Cabré Anna¹,González Marta¹,Ribalta Josep¹,Masana Lluís¹

Affiliation:

1. Unitat de Recerca en Lípids i Arteriosclerosi, Universitat Rovira i Virgili, IISPV, CIBERDEM, Reus 43201, Spain

Abstract

Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) positively correlates with the atherogenic dyslipidaemia characteristic of diabetic patients.

Publisher

Portland Press Ltd.

Subject

General Medicine

Link

https://portlandpress.com/clinsci/article-pdf/128/12/877/447119/cs1280877.pdf

Reference41 articles.

1. The secretory proprotein convertase neural Liver regeneration and neuronal differentiation;Seidah;Proc. Natl. Acad. Sci. U.S.A.,2003

2. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol;Benjannet;J. Biol. Chem.,2004

3. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia;Abifadel;Nat. Genet.,2003

4. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9;Cohen;Nat. Genet.,2005

5. Inflammation stimulates the expression of PCSK9;Feingold;Biochem. Biophys. Res. Commun.,2008

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors;Tzu Chi Medical Journal;2024-09-05

2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in patients with end‐stage renal disease;European Journal of Clinical Investigation;2024-06-10

3. Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody;CPT: Pharmacometrics & Systems Pharmacology;2023-11-22

4. High-Fat Diet Enhances Platelet Activation and Is Associated with Proprotein Convertase Subtilisin Kexin 9: An Animal Study;Nutrients;2023-10-21

5. The Effect of PCSK9 Inhibition on the Stabilization of Atherosclerotic Plaque Determined by Biochemical and Diagnostic Imaging Methods;Molecules;2023-08-07